3SBio Inc. and Taiwan Liposome Company, Ltd. (TLC) have announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX™ technology platform in the therapeutic areas of oncology and severe infectious diseases.

Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, and TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialize in mainland China. 

The two companies also agreed to further collaboration in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.

Under the terms of the agreement, TLC is eligible to receive up to US$25 million in upfront payments for each product and subsequent regulatory and sales milestone payments. TLC is also eligible a share of the potential profits from product sales. Additional financial terms were not disclosed.